المؤلفون: Paulissen, Jeroen H.J., Seddik, Ahmed H., Dunton, Kyle J., Livings, Christopher J., van Hulst, Marinus, Postma, Maarten J., de Jong, Lisa A., Freriks, Roel D.

المصدر: Paulissen , J H J , Seddik , A H , Dunton , K J , Livings , C J , van Hulst , M , Postma , M J , de Jong , L A & Freriks , R D 2024 , ' Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland ' , European Journal of Health Economics , vol. 25 , pp. 689–699 . https://doi.org/10.1007/s10198-023-01617-3

مصطلحات موضوعية: Breast cancer, Cost-effectiveness, HER2-positive, Metastatic, Trastuzumab deruxtecan

وصف الملف: application/pdf

الاتاحة: https://hdl.handle.net/11370/dc98b59b-1a54-47a0-a4b5-42f42ed50467
https://research.rug.nl/en/publications/dc98b59b-1a54-47a0-a4b5-42f42ed50467
https://doi.org/10.1007/s10198-023-01617-3
https://pure.rug.nl/ws/files/1065407607/s10198-023-01617-3.pdf
http://www.scopus.com/inward/record.url?scp=85165570907&partnerID=8YFLogxK

المؤلفون: Paulissen, Jeroen H. J., Seddik, Ahmed H., Dunton, Kyle J., Livings, Christopher J., van Hulst, Marinus, Postma, Maarten J., de Jong, Lisa A., Freriks, Roel D.

المصدر: European Journal of Health Economics; Jun2024, Vol. 25 Issue 4, p689-699, 11p

مصطلحات موضوعية: METASTATIC breast cancer, HER2 positive breast cancer, TRASTUZUMAB, COST effectiveness, QUALITY-adjusted life years

مصطلحات جغرافية: FINLAND

الشركة/الكيان: HELSINGIN yliopisto